Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population
10.3346/jkms.2019.34.e224
- Author:
Morena USTULIN
1
;
So Young PARK
;
Hangseok CHOI
;
Suk CHON
;
Jeong Taek WOO
;
Sang Youl RHEE
Author Information
1. Medical Science Research Institute, Kyung Hee University Medical Center, Seoul, Korea. bard95@hanmail.net
- Publication Type:Original Article
- Keywords:
Type 2 Diabetes Mellitus;
Fractures;
Osteoporosis;
Dipeptidyl-Peptidase IV Inhibitors
- MeSH:
Cohort Studies;
Comorbidity;
Diabetes Complications;
Diabetes Mellitus, Type 2;
Diagnosis;
Dipeptidyl-Peptidase IV Inhibitors;
Dyslipidemias;
Femoral Fractures;
Fractures, Bone;
Hypertension;
Incidence;
National Health Programs;
Osteoporosis;
Osteoporotic Fractures
- From:Journal of Korean Medical Science
2019;34(35):e224-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: There have been equivocal results in studies of the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i) on fractures. In this study, we analyzed the effect of DPP-4i on bone fracture risk in a Korean population. METHODS: We extracted subjects (n = 11,164) aged 50 years or older from the National Health Insurance Service–National Sample Cohort 2.0 from 2009 to 2014. Our control group included subjects without diabetes (n = 5,582), and our treatment groups with diabetes included DPP-4i users (n = 1,410) and DPP-4i non-users (n = 4,172). The primary endpoint was the incidence of a composite outcome consisting of osteoporosis diagnosis, osteoporotic fractures, vertebral fractures, non-vertebral fractures, and femoral fractures. The secondary endpoint was the incidence of each individual component of the composite outcome. Survival analysis was performed with adjustment for age, gender, diabetes complications severity index, Charlson comorbidity index, hypertension medication, and dyslipidemia treatment. RESULTS: The incidence of the composite outcome per 1,000 person-years was 0.089 in DPP-4i users, 0.099 in DPP-4i non-users, and 0.095 in controls. There was no significant difference in fracture risk between DPP-4i users and DPP-4i non-users or controls after the adjustments (P > 0.05). The incidences of osteoporosis diagnosis, osteoporotic fractures, vertebral fractures, non-vertebral fractures, and femoral fractures were not significantly different between DPP-4i users and non-users. The results of subgroup analyses by gender and age were consistent. CONCLUSION: DPP-4i had no significant effect on the risk of fractures in a Korean population.
